Physician profile
Cheryl D Eley
NPI 1225066228
$1,936.63
in general payments reported to CMS, 2019-2025
19 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $413 · 2021: $470 · 2022: $74.49 · 2023: $202 · 2024: $361 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $339.65 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $272.77 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $215.98 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $205.49 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $133.31 | 2021-2024 | Azstarys |
| Sobi, INC | $94.21 | 2020-2021 | |
| Pfizer INC. | $90.47 | 2019-2024 | |
| Sanofi Pasteur INC. | $87.06 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $86.79 | 2024-2025 | |
| Adlon Therapeutics L.P. | $69.80 | 2019-2021 | |
| Alk-Abello, INC | $68.17 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Takeda Pharmaceuticals U.S.A., INC. | $65.50 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $54.56 | 2024-2025 | Relexxii |
| Genentech USA, INC. | $47.41 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $32.21 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.58 | 2024 | Id Now Instrument |
| Phadia US INC. | $18.07 | 2021 | |
| Cipher Pharmaceuticals US LLC | $17.74 | 2025 | Natroba, Spinosad |
| Glaxosmithkline, LLC. | $16.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Eley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.